

Form 51-102F3
MATERIAL CHANGE REPORT

Item 1. Name and Address of Reporting Issuer

NervGen Pharma Corp. (“**NervGen**” or the “**Company**”)

Suite 1703, Three Bentall Centre
595 Burrard Street
Vancouver, BC V7X 1J1

Item 2. Date of Material Changes

April 22, 2021

Item 3. News Releases

A news release announcing the material change was disseminated on April 22, 2021 through Newsfile Corp’s distribution network and a copy was filed on NervGen’s SEDAR profile at www.sedar.com.

Item 4. Summary of Material Changes

On March 22, 2021, NervGen announced the appointment of Daniel Mikol, MD, PhD, as the Company’s Chief Medical Officer, effective May 5th, 2021.

Item 5. Full Description of Material Changes

On April 22, 2021, NervGen announced the appointment of Daniel Mikol, MD, PhD, as the Company’s Chief Medical Officer, effective May 5th, 2021.

Dr. Mikol is a Board Certified Neurologist with 13 years of pharmaceutical industry experience focused on neurodegenerative diseases. Currently, Dr. Mikol holds the position of Executive Medical Director, Global Clinical Development at Amgen in Thousand Oaks, California where he is the global development therapeutic area head for neuroscience and nephrology, and head of the molecular genetic team for all therapeutic areas. At Amgen, Dr. Mikol was instrumental as a development lead in achieving regulatory approval of erenumab for migraine prevention. Prior to working at Amgen, Dr. Mikol was a Senior Medical Director at Biogen, where amongst other responsibilities, he was the clinical development lead for natalizumab (Tysabri) and helped Biogen in gaining their Japanese (PMDA) approval for relapsing multiple sclerosis. Dr. Mikol has also held positions at Novartis and EMD Serono where he worked with, amongst other therapies, fingolomid, cladribine and interferon- β -1a. Dr. Mikol was educated at the University of Chicago for both his MD and PhD, and was a Fulbright Scholar, Immunological Research, Ludwig Maximilian University of Munich, Germany. He held a staff physician role treating patients for 12 years at The University of Michigan, Department of Neurology.

Item 6. Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable.

Item 7. **Omitted Information**

No information has been omitted on the basis that it is confidential information.

Item 8. **Executive Officer**

William Adams, Chief Financial Officer

Suite 1703, Three Bentall Centre
595 Burrard Street
Vancouver, BC V7X 1J1

Item 9. **Date of Report**

April 23, 2021